局部晚期鼻咽癌患者在标准放化疗后存在局部和/或区域残留病灶时进行放疗剂量递增:一项非随机观察性研究
该研究纳入2011年11月至2020年11月间259例诱导化疗联合同期放化疗后存在局部和/或区域残留病灶的局部晚期鼻咽癌患者,评估放疗剂量递增的疗效与毒性。原发灶放疗总剂量68.1-74.25 Gy(中位70.4 Gy),推量剂量4.0-18.0 Gy(中位9 Gy),每次1.8-2.0 Gy。5年局部无复发生存率90.2%,区域无复发生存率89.1%,总生存率86.3%。作者认为推量放疗是此类患者的一种选择,需进一步前瞻性研究。
要点
- 259例局部晚期鼻咽癌标准放化疗后残留病灶患者接受推量放疗,中位推量剂量9 Gy。
- 全组5年总生存率86.3%,局部无复发生存率90.2%,区域无复发生存率89.1%。
- 局部和区域均有残留者3年无远处转移生存率和总生存率最差。
核心结论
- 作者认为推量放疗是局部晚期鼻咽癌患者接受诱导化疗联合同期放化疗后存在局部和/或区域残留病灶时的一种选择,但需进一步前瞻性研究。
研究设计与样本
- 非随机观察性研究,纳入2011年11月至2020年11月间在本院接受诱导化疗联合同期放化疗后存在局部和/或区域残留病灶的259例局部晚期鼻咽癌患者。
- 原发灶放疗总剂量68.1-74.25 Gy(中位70.4 Gy),推量剂量4.0-18.0 Gy(中位9 Gy),每次1.8-2.0 Gy。
- 试验为回顾性注册。
主要发现
- 全组5年局部无复发生存率90.2%,区域无复发生存率89.1%,局部区域无复发生存率79.5%,无远处转移生存率87.9%,无失败生存率69.0%,总生存率86.3%。
- 年龄≤65岁与>65岁、血浆EBV-DNA≤500与>500、T1-2与T3-4、N0-1与N2-3、III期与IV期患者的局部区域无复发生存率、无远处转移生存率、无失败生存率和总生存率均无统计学显著差异。
- 原发灶放疗与推量之间的间隔不是局部区域无复发生存率、无远处转移生存率、无失败生存率和总生存率的预后因素。
- 男性3年无失败生存率低于女性(72.9% vs 83.7%,P=0.024)。
- 局部和区域均有残留者的3年无远处转移生存率(77.7% vs 98.8% vs 87.4%,P=0.014)和总生存率(75.9% vs 94.5% vs 82.4%,P=0.002)在三组中最差。
临床怎么用
- 作者认为推量放疗是局部晚期鼻咽癌患者接受诱导化疗联合同期放化疗后存在局部和/或区域残留病灶时的一种选择。
局限性
- 原文结论指出需进一步前瞻性研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: To assess the effectiveness and toxicity of radiation dose escalation for locally advanced nasopharyngeal carcinoma (LA-NPC) in patients with local and/or regional residual lesion(s) after standard treatment. METHODS: From November 2011 to November 2020, 259 LA-NPC patients who had local and/or regional residual lesion(s) after induction chemotherapy followed by concurrent chemoradiotherapy (IC + CCRT) from our hospital were included. The total dose of primary radiotherapy (RT) was 68.1-74.25 Gy (median, 70.4 Gy). The boost doses were 4.0-18.0 Gy (median, 9 Gy), 1.8-2.0 Gy/fraction. RESULTS: For all patients, the 5-year local relapse-free survival was 90.2%, regional relapse-free survival was 89.1%, locoregional relapse-free survival (LRRFS) was 79.5%, distant metastasis-free survival (DMFS) was 87.9%, failure-free survival (FFS) was 69.0%, and overall survival (OS) was 86.3%. LRRFS, DMFS, FFS, and OS in patients with age ≤ 65 versus > 65, plasma Epstein-Barr virus-deoxyribonucleic acid ≤ 500 versus > 500, T1-2 versus T3-4, N0-1 versus N2-3, and stage III versus stage IV showed no statistically significant differences. The interval between primary RT and boost was not a prognostic factor for LRRFS, DMFS, FFS, and OS. Males had a lower 3-year FFS rate than females (72.9% vs. 83.7%, P = 0.024). LA-NPCs with locally and regionally residual lesion(s) had the worst 3-year DMFS and OS rates compared with locally or regionally residual lesion(s) (77.7% vs. 98.8% vs. 87.4%, P = 0.014; 75.9% vs. 94.5% vs. 82.4%, P = 0.002). CONCLUSION: Boost radiation was an option for LA-NPCs with locally and/or regionally residual lesions after receiving IC + CCRT. It warrants further prospective study. TRIAL REGISTRATION: Retrospectively registered.
引用
- Jin T, Liu NF, Jin QF, et al. Radiation dose escalation for locally advanced nasopharyngeal carcinoma patients with local and/or regional residual lesions after standard chemoradiotherapy: a non-randomized, observational study. Radiat Oncol. 2022. PMID: 36345003. doi:10.1186/s13014-022-02147-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。